Class information for:
Level 1: GENERIC SUBSTITUTION//GENERIC DRUGS//REFERENCE PRICING

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
5869 1495 28.4 45%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1294 8163 FOOD AND DRUG LAW JOURNAL//GENERIC SUBSTITUTION//DIRECT TO CONSUMER ADVERTISING

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 GENERIC SUBSTITUTION Author keyword 89 75% 4% 65
2 GENERIC DRUGS Author keyword 34 36% 5% 75
3 REFERENCE PRICING Author keyword 31 73% 2% 24
4 DEMAND SIDE MEASURES Author keyword 31 92% 1% 12
5 GENERIC MEDICINES Author keyword 30 68% 2% 27
6 PARALLEL IMPORTS Author keyword 25 66% 2% 23
7 GENERIC ENTRY Author keyword 24 91% 1% 10
8 BRAND NAME DRUG Author keyword 21 85% 1% 11
9 GENERICS Author keyword 16 25% 4% 56
10 PARALLEL TRADE Author keyword 15 67% 1% 14

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 GENERIC SUBSTITUTION 89 75% 4% 65 Search GENERIC+SUBSTITUTION Search GENERIC+SUBSTITUTION
2 GENERIC DRUGS 34 36% 5% 75 Search GENERIC+DRUGS Search GENERIC+DRUGS
3 REFERENCE PRICING 31 73% 2% 24 Search REFERENCE+PRICING Search REFERENCE+PRICING
4 DEMAND SIDE MEASURES 31 92% 1% 12 Search DEMAND+SIDE+MEASURES Search DEMAND+SIDE+MEASURES
5 GENERIC MEDICINES 30 68% 2% 27 Search GENERIC+MEDICINES Search GENERIC+MEDICINES
6 PARALLEL IMPORTS 25 66% 2% 23 Search PARALLEL+IMPORTS Search PARALLEL+IMPORTS
7 GENERIC ENTRY 24 91% 1% 10 Search GENERIC+ENTRY Search GENERIC+ENTRY
8 BRAND NAME DRUG 21 85% 1% 11 Search BRAND+NAME+DRUG Search BRAND+NAME+DRUG
9 GENERICS 16 25% 4% 56 Search GENERICS Search GENERICS
10 PARALLEL TRADE 15 67% 1% 14 Search PARALLEL+TRADE Search PARALLEL+TRADE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 GENERIC ENTRY 32 88% 1% 15
2 DRUG SUBSTITUTION 21 78% 1% 14
3 CARBAMAZEPINE FORMULATIONS 18 89% 1% 8
4 PRESCRIPTION DECISION 17 79% 1% 11
5 GENERIC SUBSTITUTION 17 54% 1% 22
6 LOW PRICES 15 88% 0% 7
7 BRAND NAME 14 28% 3% 42
8 GROSS PROFITABILITY 14 100% 0% 7
9 PRESCRIBING EFFICIENCY 13 71% 1% 10
10 DRUG EXPENDITURE 12 75% 1% 9

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease A Systematic Review and Meta-analysis 2008 119 66 52%
Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications 2014 3 21 81%
Systematic review of factors affecting pharmaceutical expenditures 2014 3 46 61%
Generic and therapeutic substitutions in the UK: are they a good thing? 2010 44 11 64%
Demand-side policies to encourage the use of generic medicines: an overview 2013 9 80 84%
Efficacy and Safety of Innovator versus Generic Drugs in Patients with Epilepsy: A Systematic Review 2012 8 20 85%
A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study 2013 8 47 77%
Current approaches to the use of generic antiepileptic drugs 2007 34 20 90%
Switching from Brand-Name to Generic Psychotropic Medications: A Literature Review 2011 17 56 82%
The impact of reference-pricing systems in Europe: a literature review and case studies 2011 12 20 95%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SCI TECHNOL INNOVAT NEGLECTED DIS 12 86% 0.4% 6
2 PUBL HLTH INTELLIGENCE STRATEG BUSINESS UNIT 6 80% 0.3% 4
3 SOCIAL POLICY LSE HLTH 6 80% 0.3% 4
4 LIVERPOOL HLTH ECON 5 55% 0.4% 6
5 P CRIBING GRP 5 29% 0.9% 14
6 BARCELONA HLTH REG 4 75% 0.2% 3
7 ECON HLTH C 3 50% 0.3% 5
8 MED REIMBURSEMENT 3 57% 0.3% 4
9 HEALTHCARE MANAGEMENT PROGRAMME 3 100% 0.2% 3
10 TECHNOL DEV HLTH 2 38% 0.3% 5

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000203418 GRAY MARKETS//PARALLEL IMPORTATION//TEXTBOOK MARKET
2 0.0000187765 INTELLECTUAL PROPERTY PROGRAM//CARDIORENAL DRUGS//FOOD DRUG GRP
3 0.0000166509 MEDICARE PART D//PRIOR AUTHORIZATION//CO PAYMENT
4 0.0000130990 DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS
5 0.0000127528 COMPULSORY LICENSING//ACCESS TO MEDICINES//DOHA DECLARATION
6 0.0000108279 CARDIOVASC METABOL SERV//FORMULARY DEV//SPECIALTY DRUGS
7 0.0000094165 PHARMACEUTICAL ASSISTANCE//JUDICIAL DECISIONS//NATIONAL POLICY OF PHARMACEUTICAL ASSISTANCE
8 0.0000088113 INDIVIDUAL BIOEQUIVALENCE//HIGHLY VARIABLE DRUGS//BIOEQUIVALENCE
9 0.0000081923 PRESCRIBING INDICATORS//PRESCRIBING COSTS//FUNDHOLDING
10 0.0000081787 ORPHAN DRUGS//RARE DISEASES//OFF ORPHAN PROD DEV